Fostamatinib
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB12010 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 100 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | autosomal thrombocytopenia with normal platelets | KG + DL |
| 2 | non-syndromic esophageal malformation | KG + DL |
| 3 | syndromic constitutional thrombocytopenia | KG + DL |
| 4 | glaucoma | KG + DL |
| 5 | biotin metabolic disease | KG + DL |
| 6 | primary hereditary glaucoma | KG + DL |
| 7 | open-angle glaucoma | KG + DL |
| 8 | filariasis | KG + DL |
| 9 | vitamin deficiency disorder | KG + DL |
| 10 | esophageal disease | KG + DL |
| 11 | neonatal thrombocytopenia | KG + DL |
| 12 | tinea nigra | KG + DL |
| 13 | anogenital human papillomavirus infection | KG + DL |
| 14 | herpes simplex virus keratitis | KG + DL |
| 15 | HER2 positive breast carcinoma | KG + DL |
| 16 | photosensitivity disease | KG + DL |
| 17 | female breast carcinoma | KG + DL |
| 18 | esotropia | KG + DL |
| 19 | progesterone-receptor negative breast cancer | KG + DL |
| 20 | normal breast-like subtype of breast carcinoma | KG + DL |
| 21 | progesterone-receptor positive breast cancer | KG + DL |
| 22 | breast tumor luminal A or B | KG + DL |
| 23 | rectal cloacogenic carcinoma | KG + DL |
| 24 | dermatophytosis | KG + DL |
| 25 | thrombotic disease | KG + DL |
| 26 | urethral verrucous carcinoma | KG + DL |
| 27 | gallbladder adenosquamous carcinoma | KG + DL |
| 28 | esophagus verrucous carcinoma | KG + DL |
| 29 | adenosquamous prostate carcinoma | KG + DL |
| 30 | lung occult squamous cell carcinoma | KG + DL |
| 31 | non-small cell squamous lung carcinoma | KG + DL |
| 32 | carcinoma of lip | KG + DL |
| 33 | acantholytic variant squamous cell breast carcinoma | KG + DL |
| 34 | adenosquamous breast carcinoma | KG + DL |
| 35 | external ear basal cell carcinoma | KG + DL |
| 36 | esophageal basaloid carcinoma | KG + DL |
| 37 | spindle cell variant squamous cell breast carcinoma | KG + DL |
| 38 | metaplastic breast carcinoma | KG + DL |
| 39 | pancreatic adenosquamous carcinoma | KG + DL |
| 40 | glottis squamous cell carcinoma | KG + DL |
| 41 | maxillary sinus carcinoma | KG + DL |
| 42 | lacrimal gland carcinoma | KG + DL |
| 43 | large cell keratinizing variant squamous cell breast carcinoma | KG + DL |
| 44 | non-keratinizing sinonasal squamous cell carcinoma | KG + DL |
| 45 | ethmoid sinus squamous cell carcinoma | KG + DL |
| 46 | cervical verrucous carcinoma | KG + DL |
| 47 | thymic basaloid carcinoma | KG + DL |
| 48 | sarcomatoid squamous cell skin carcinoma | KG + DL |
| 49 | vulva verrucous carcinoma | KG + DL |
| 50 | adenosquamous lung carcinoma | KG + DL |
(Showing top 50 of 100 predictions)
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.